Lineage Cell Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
LCTX$1.08+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $40,791 | $45,789 |
| Marketable securities | 14,990 | 2,016 |
| Accounts receivable | 891 | 638 |
| Prepaid expenses and other current assets | 2,485 | 2,554 |
| Total current assets | 59,157 | 50,997 |
| NONCURRENT ASSETS | ||
| Property and equipment, net | 2,566 | 2,251 |
| Operating lease right-of-use assets | 2,131 | 2,144 |
| Deposits and other long-term assets | 558 | 614 |
| Goodwill | 10,672 | 10,672 |
| Intangible assets, net | 31,700 | 46,540 |
| Deferred tax asset, net | 5,800 | — |
| TOTAL ASSETS | $112,584 | $113,218 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued liabilities | $7,181 | $5,437 |
| Operating lease liabilities, current portion | 816 | 1,097 |
| Finance lease liabilities, current portion | 37 | 55 |
| Deferred revenues, current portion | 3,333 | 7,388 |
| Total current liabilities | 11,367 | 13,977 |
| LONG-TERM LIABILITIES | ||
| Deferred tax liability, net | 22 | 273 |
| Deferred revenues, net of current portion | 12,377 | 14,433 |
| Operating lease liabilities, net of current portion | 1,534 | 1,295 |
| Finance lease liabilities, net of current portion | 32 | 67 |
| Warrant liabilities | 43,906 | 6,161 |
| TOTAL LIABILITIES | 69,238 | 36,206 |
| Commitments and contingencies (Note 13) | ||
| SHAREHOLDERS’ EQUITY | ||
| Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of December 31, 2025 and 2024 | — | — |
| Common shares, no par value, 450,000 shares authorized as of December 31, 2025 and 2024; 243,122 and 220,416 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 515,467 | 484,722 |
| Accumulated other comprehensive loss | (3,920) | (2,876) |
| Accumulated deficit | (466,998) | (403,465) |
| Lineage's shareholders’ equity | 44,549 | 78,381 |
| Noncontrolling deficit | (1,203) | (1,369) |
| Total shareholders’ equity | 43,346 | 77,012 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $112,584 | $113,218 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.